Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial

Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, combined with two adjuvants, alum and Dynavax Technologies Corporation’s DVAX CpG 1018.
Over 4,000 volunteers in the U.K. have been randomized in the Phase 3 trial “Cov-Compare,” which compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca Plc’s AZN conditionally approved vaccine, Vaxzevria1.
Topline data are expected by September 2021, and submission to the U.K.’s Medicines and Healthcare products Regulatory Agency for regulatory approval will follow.
Price Action: DVAX shares are up 2.02% at $8.59 during the market session on the last check Thursday.